An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. (Q30384418)

21 June 2017

title

An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. (English)

1 reference

21 June 2017

0 references

1 reference

Falko Schmeisser

1

1 reference

21 June 2017

Galina M Vodeiko

2

1 reference

21 June 2017

Vladimir Y Lugovtsev

3

1 reference

21 June 2017

Richard R Stout

4

1 reference

21 June 2017

Jerry P Weir

5

1 reference

21 June 2017

language of work or name

English

0 references

publication date

12 January 2010

1 reference

21 June 2017

1 reference

21 June 2017

volume

28

1 reference

21 June 2017

issue

12

1 reference

21 June 2017

page(s)

2442-2449

1 reference

An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: Application for potency determinations of inactivated whole virus and subunit vaccines

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

The annual production cycle for influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Crystalline Antigen from the Influenza Virus Envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Influenza virus proteins. I. Analysis of polypeptides of the virion and identification of spike glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Emergence of a novel swine-origin influenza A (H1N1) virus in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Rapid and selective characterization of influenza virus constituents in monovalent and multivalent preparations using non-porous reversed-phase high performance liquid chromatography columns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Influenza virus matrix protein is the major driving force in virus budding.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

New developments in the measurement of the hemagglutinin content of influenza virus vaccines by single-radial-immunodiffusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.079

10.1016/J.VACCINE.2009.12.079

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference